title: Introduction and commentary: paving the way for biosimilars in oncology, part 2: focus on safety and clinical trial considerations.
authors.affiliation: Director, Breast Oncology Program Taussig Cancer Institute Cleveland Clinic Cleveland, OH. Electronic address: abrahaj5@ccf.org.
authors.forename: Jame
authors.initials: J
authors.lastname: Abraham
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D059451:Biosimilar Pharmaceuticals